Hikma Pharmaceuticals (LON:HIK – Free Report) had its target price lowered by Berenberg Bank from GBX 2,100 to GBX 2,050 in a research note released on Monday morning,Digital Look reports. The firm currently has a buy rating on the stock.
Other research analysts have also issued reports about the stock. Deutsche Bank cut their target price on shares of Hikma Pharmaceuticals from GBX 2,050 to GBX 2,000 and set a “buy” rating on the stock in a research note on Friday, November 6th. Citigroup raised their price target on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,025 price target on shares of Hikma Pharmaceuticals in a research note on Thursday, November 5th. Four analysts have rated the stock with a Buy rating. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of GBX 1,986.25.
Check Out Our Latest Analysis on HIK
Hikma Pharmaceuticals Stock Performance
Shares of HIK stock opened at GBX 1,644 on Monday. The firm has a 50 day moving average of GBX 1,628.83 and a 200-day moving average of GBX 1,510.19. The company has a market cap of £3.40 billion, a price-to-earnings ratio of 9.34, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. Hikma Pharmaceuticals has a 52 week low of GBX 1,187 and a 52 week high of GBX 1,762.
About Hikma Pharmaceuticals
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.
Further Reading
- Five stocks we like better than Hikma Pharmaceuticals
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
